Gracell Biotechnologies

Gracell Biotechnologies, Inc. engages in the research and development activities of biotechnological and pharmaceutical industries. The firm through its FasTCAR and TruUCAR platforms, it is developing a pipeline of autologous and allogeneic cell therapy candidates with the potential to treat both hematologic malignancies and solid tumors. The company was founded by William Wei Cao in 2017 and is headquartered in Suzhou, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Gracell Biotechnologies reports solid financials and advances lead CAR-T therapy

Gracell Biotechnologies showcased strong financials and promising progress with their lead CAR-T therapy GC012F for multiple myeloma.
While facing challenges in trial optimization and enrollment, the company is well-positioned to leverage partnerships and drive future growth.
Opportunities lie in expanding partnerships, generating durability data, and prioritizing pipeline development to enhance market competitiveness and patient outcomes.

Gracell Biotechnologies reports Q1 loss, advances CAR-T therapy pipeline

Gracell Biotechnologies faces financial challenges with a net loss in Q1 2023 but maintains a strong cash position for future operations.
The company's focus on advancing CAR-T therapy, particularly GC012F, and venturing into autoimmune disease clinical development highlight strategic growth initiatives.

Gracell Biotechnologies excels in Q2 with promising trial results and funding success

Gracell Biotechnologies showcased strong performance in Q2 2023 with positive trial results and successful fundraising, underlining their commitment to innovation and growth.
While facing challenges in communication and sustaining trial outcomes, the company's strategic strengths and opportunities position them for future success in the biotech sector.
Investors should take note of Gracell's progress in advancing novel therapies like GC012F and their financial stability, signaling potential for long-term value creation.

Gracell Biotechnologies reports strong Q3 performance and advances CAR-T therapies

Gracell Biotechnologies reported positive financial performance and strong clinical data, positioning the company well for future growth and innovation.
While facing challenges such as limited information availability and regulatory complexities, the company remains focused on advancing its CAR-T therapies and addressing unmet medical needs.
Opportunities lie in leveraging financial strength to attract partners, showcasing research at industry events, and advancing clinical programs for myeloma and autoimmune diseases.
Overall, Gracell Biotechnologies' emphasis on safety, efficacy, and innovation underscores its commitment to developing transformative therapies for patients in need.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

The stock price of Gracell Biotechnologies Inc (NASDAQ: GRCL) increased by over 70% during intraday trading today. This is why it happened.

Gracell Biotechnologies (GRCL) Stock: Why The Price Surged Today

SUZHOU, China and PALO ALTO, Calif., Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that members of its senior management team, including its Chairman of Board and Chief Executive Officer Dr. William (Wei) Cao, Chief Financial Officer Dr. Yili Kevin Xie and Chief Medical Officer Dr. Martina A.

Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.

Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma

SUZHOU, China and PALO ALTO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd.

Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the third quarter of the year and provided recent business highlights.

Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU and SHANGHAI, China, and PALO ALTO, California, Nov. 4, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced preclinical data for GC502, an allogeneic chimeric antigen receptor (CAR) T cell therapy for the treatment of B-cell malignancies, will be presented as a virtual poster at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as part of the "Cellular Immunotherapies: Basic and Translational" session on December 11, 2021 from 5:30 p.m.-7:30 p.m.(EST).

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting

SUZHOU, China and PALO ALTO, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September

Gracell Biotechnologies, Inc. (GRCL) CEO William Wei Cao on Q2 2021 Results - Earnings Call Transcript

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the second quarter of the year and recent business highlights. Gracell will host a conference call today, Tuesday, August 17, at 8:00 am Eastern Time.

Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an exclusive license agreement with FutureGen Biopharm ("FutureGen"), an innovative biopharmaceutical company, to develop engineered immune cell therapies targeting Claudin 18.2 ("CLDN18.2") in solid tumors.

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the BTIG Virtual Biotechnology Conference 2021 (details below).

Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Rating Upgrade to Buy

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress. The conference call and webcast have been rescheduled to a time after the release of the e-poster presentation at the EHA 2021 Virtual Congress. Details for the rescheduled conference call are as follows:

Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a key opinion leader (KOL) webinar on the challenges of treating High Risk Multiple Myeloma and a potential novel approach on Friday, June 11, 2021 at 8:00am Eastern Time.

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in relapsed/refractory multiple myeloma. This data was accepted as poster presentation at the 2021 American Society of Clinical Oncology Annual Meeting.

Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 /PRNewswire/ --  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated results of their first-in-human multicenter study of GC012F for the treatment of relapsed and/or refractory multiple myeloma, a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy currently in development for the treatment of multiple myeloma, at the 2021 American Society of Clinical Oncology ("ASCO") Annual Meeting and the European Hematology Association 2021 ("EHA2021") Congress.

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting

Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU and SHANGHAI, China, May 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Dr. Jenny (Yajin) Ni as its Chief Technology Officer (CTO). In her role, Dr. Ni will be responsible for strategically leading CAR-T product development, Chemistry, Manufacturing, and Control (CMC), and supply chain management activities.

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission (“SEC”) on April 23, 2021.

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

Alimera Sciences

Eli Lilly

Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's.

Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines

SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) in an e-poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting on April 10. TruUCAR-enabled GC027 is a first-in-human, off-the-shelf allogeneic CAR-T stand-alone therapy targeting CD7.

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting

SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference (details below).

News for Gracell Biotechnologies Stock (GRCL)